79 results on '"Uemura, Hiroji"'
Search Results
2. Association of PSA variability with prostate cancer development using large-scale medical information data: a retrospective cohort study
3. Localized amyloidosis of the ureter: a case report
4. Transurethral laser lithotripsy using the Mitrofanoff urethral conduit for bladder stones: a case report
5. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
6. A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
7. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
8. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
9. Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
10. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
11. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
12. Effectiveness and Feasibility of Up-Front Docetaxel Chemotherapy for Japanese Metastatic Hormone-Naïve Prostate Cancer
13. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
14. Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
15. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
16. The impact of smoking on male lower urinary tract symptoms (LUTS)
17. Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
18. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
19. Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
20. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
21. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
22. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
23. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
24. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
25. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
26. Successful removal of an encrusted metallic ureteral stent using a disposable ureteroscope and Ho:YAG laser lithotripsy
27. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
28. A case of allograft ureteral stone successfully treated with antegrade ureteroscopic lithotripsy: use of a 3D-printed model to determine the ideal approach
29. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
30. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
31. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
32. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
33. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
34. Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure
35. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
36. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma
37. Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report
38. Paraganglioma in the bladder: a case report
39. A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy
40. Ureter metastatic castration-resistant prostate cancer: a case report
41. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
42. Enterogenous cyst of pediatric testis: a case report
43. The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis
44. Port site recurrence after laparoscopic radical nephrectomy: a case report
45. Onco-testicular sperm extraction (onco-TESE) for bilateral testicular tumors: two case reports
46. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
47. Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
48. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival
49. Developing a preoperative predictive model for ureteral length for ureteral stent insertion
50. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.